CALIFORNIA ENVIRONMENTAL PROTECTION AGENCY  
DEPARTMENT OF PESTICIDE REGULATION  
MEDICAL TOXICOLOGY BRANCH  

SUMMARY OF TOXICOLOGY DATA  
ACEPHATE  

Chemical Code # 001685, DPN # 00108  
SB 950 # 125  

October 1, 1986  
Revised 2/5/87; 1/25/88; 7/2/88; 11/7/88; 4/6/90; 5/5/93, 2/8/02, 6/7/02, 10/01/03, 1/06/04,  
2/9/04 8/17/05, 3/13/08, and 5/5/08  

I. DATA GAP STATUS  

Combined, rat: No data gap, no adverse effect  
Chronic toxicity, rat: See Combined, rat  
Chronic toxicity, dog: No data gap, possible adverse effect  
Oncogenicity, rat: See Combined, rat  
Oncogenicity, mouse: No data gap, possible adverse effect  
Reproduction, rat: No data gap, no adverse effect  
Teratology, rat: No data gap, no adverse effect  
Teratology, rabbit: No data gap, no adverse effect  
Gene mutation: No data gap, possible adverse effect  
Chromosome effects: No data gap, possible adverse effect  
DNA damage: No data gap, possible adverse effect  
Neurotoxicity: No data gap, possible adverse effect (rats)  

Toxicology one-liners are attached.  
** Indicates an acceptable study. **Bold face** indicates a possible adverse effect.  
Filename: t20080505.wpd  
Revised by M. Silva, 11/88 and 4/90; Kellner, 5/5/93, Gee, 2/8/02, 6/7/02, 10/01/03, 1/5/04,  
2/9/04 and 8/17/05, and Aldous, 3/13/08 and 5/5/08.  

All record numbers for the above study types through 238758 (Document No. 108-0354) were  
examined. This includes all relevant studies indexed by DPR as of 4/21/08.  
These pages contain summaries only. Each individual worksheet may contain additional effects.
II. TOXICOLOGY ONE-LINERS AND CONCLUSIONS

COMBINED, RAT

** 139, 144  037723, 037728  “Lifetime Oral Toxicity/Carcinogenicity Study with Technical RE-12420 (Orthene) in Rats.”  (Bio/dynamics, 6/30/81).  Acephate (92.4%, lot SX-992) fed in the diet at 0, 5, 50 or 700 ppm (0.24/0.31, 2.44/3.06 or 38.2/47.2 mg/Kg, M/F), 80/sex/group; significantly lower body weight in males at high dose; consistent cholinesterase inhibition at high dose and to a lesser extent at low and mid dose levels; systemic NOEL = 5.0 ppm (based on brain cholinesterase).  McGee evaluation (4/28/86) was unacceptable but upgradeable.  Davis evaluation (1/5/87) of supplemental data and Chevron response was complete and ACCEPTABLE.
No EPA one-liner available.

067  973192  Interim report for record 037723.

067  973187  Supplement to record 037723--photomicrographs.

136  026943  Supplement to 037723--discussion of amendments to report.

146  037732  Supplement to 037723--rationale for amendments to report.

067  971388  Less complete version of study identified as record 037723.  Reviewed by J. Wong, 5/22/85, with insufficient information for evaluation.

050280  (Bio/Dynamics, 3/20/78)  Supplement to 108-139 to 144 and 108-46, 037723-8 --Diet analysis data.  Samples from cage hoppers after 3-4 days were 93.1% of nominal for the 5 ppm level, 81.8% for the 50 ppm level, and 80.7% for the 700 ppm level.  Problems in the diet analysis included acephate found in the negative control samples between 5/5/78 and 7/3/78, corrections needed in the calculations on most pages, and missing chromatograms.  With this addendum and the information from the Chevron response of 11/24/86, the study is complete and ACCEPTABLE.  Davis 1/5/87.

161  Rebuttal of 11/20/86 to DPR review of 037723-8.

CHRONIC TOXICITY, RAT

015  973190  Invalid IBT study, 1/29/73.

CHRONIC TOXICITY, DOG

** 108-238  096115  “One-Year Oral Toxicity Study in Dogs with Chevron Acephate Technical.”  (D. W. Dalgard, Hazleton Washington, HWA 2107-165, 1/25/91).  Acephate technical, purity of 99.9%, was administered in the feed at concentrations of 0, 10, 120 (reduced from 200 ppm during week 2 of study), or 800 ppm to 5 Beagle dogs/sex/group for 1 year.  High-dose groups had lower red cell mass indices, elevated APTT and increased liver weights.
Liver pathology (perivascular pleocellular infiltrate and pigment in the reticuloendothelial cells) was noted in most high-dose animals and one mid-dose male (NOEL = 10 ppm/day). Significant RBC cholinesterase (ChE) inhibition for mid- and high dose groups was reported in addition to brain ChE inhibition for mid- and high dose females and all dose levels for males. ChE NOEL (females) = 10 ppm; males < 10 ppm. **Possible Adverse Effect:** Significant brain ChE inhibition (no NOEL in males). ACCEPTABLE. Kishiyama, Kellner and Aldous, 4/30/93.

108-237 095950. This submission was an adverse effect disclosure for 096115. Adverse Effect consisted of a significant (16%) inhibition of brain ChE in low dose (10 ppm) males by the end of the study. No worksheet. Kishiyama and Kellner, 4/30/93.

108-225 85614 “Four-Week Pilot Oral Toxicity Study in Dogs with Chevron Acephate Technical.” (Hazleton Laboratories, Chevron Report #2107-164). Levels of acephate of 250 and 500 ppm in the feed resulted in brain ChE levels of 6.2 and 5.0 mmol/g, respectively. A brain ChE NOEL was established at 20 ppm. No worksheet. Kellner, 5/6/93.

015 973189 “Two Year Chronic Oral Toxicity Study with RE 12420 in Beagle Dogs.” (IBT, No. C-8732, 12/28/72) Acephate (87 to 94 %, < 0.5 % methamidophos content), lots SX-257, 1st six months and SX-357, final 18 months, was fed in the diet at 0, 10, 30 or 100 ppm for two years with 4/sex/group. There was a decrease in RBC cholinesterase in both sexes at the high dose level. No adverse effects reported. UNACCEPTABLE (dose selection not adequately justified - high dose may not be sufficient, no analysis of diet for actual content, no ophthalmological exam, inadequate presentation of histopathology). Document 108-169, Record 61136, contains two validation reports including many variations between the raw data and the report and also identifies data not recorded. Not upgradeable. Wong, 5/13/85 and Gee, 1/5/88.

EPA one-liner: NOEL ≥ 100 ppm (HDT) for systemic toxicity; cholinesterase activity NOEL = 30 ppm; core grade--minimum.

161 Rebuttal of 11/20/86 to DPR review of 973189.

169 061136 Supplemental to 973189, two validation reports including variations between raw data and the report. Also, stability in dog diet over 7 days at room temperature. Gee, 1/5/88.

012 046560 One year interim report for study identified as record #973189.

170 061137 “90-Day Subacute Oral Toxicity Study with Orthene In Beagle Dogs.” (IBT, no. C9527, 8-24-71) Range finding study for record number 973189, volume 108-015. Orthene, SX-284, was administered to beagles at dietary levels of 0, 10, 30 or 100 ppm, 4/sex/group for 90 days. No abnormalities were noted in body weight, food consumption, behavior, clinical studies, necropsy or histopathology except for up to 60% RBC ChE inhibition at the high dose. Dogs were housed 4/kennel, sac 2/sex/group at 90 days, the other 2 were allowed to recover for a 40 day period. EPA has determined the study is “invalid”. Shimer, 11/10/87 and Gee, 12/30/87.

165 057929 Validation report of 061137 prepared by F. X. Kamienski of Chevron. A number of discrepancies between the raw data and the report are pointed out including the fact that the hematology, clinical chemistry and urinalysis data are from the two-year study, not the
range-finding study. Stability, chemical analyses and corrections are contained in the appendices. Gee, 12/30/87.

ONCOGENICITY, RAT

085 973195 “Oral Toxicity/Carcinogenicity Study in Technical RE 12420 in Rats.” (Bio/dynamics, 5/14/79, 77-1870). Acephate, lot 016-SFO-8847-8600, SX941 was fed to 70/sex/group at 0, 10, 50 or 250/350 ppm, Sprague-Dawley rats. The two-year study was terminated after 190 days due to the discovery of an impurity in the test article - the impurity was not identified. The ophthalmoscopic exam at three months was negative. UNACCEPTABLE, not upgradeable. Wong, 5/16/85.

ONCOGENICITY, MOUSE

** 145, 204 037729, 069074 “Orthene Technical (RE-12420) Lifetime Oral Carcinogenicity Study in Mice,” (IRDC, 2/24/82). Acephate (purity = 92.7, 92.1%; lot no. SX-1032) was fed in the diet to CD1 mice for 104 weeks at 0 (vehicle = chow), 50, 250 or 1000 ppm (7, 36 or 146 mg/kg/day) for males; 8, 42, or 167 mg/kg/day for females ) with 75/sex/group). Possible adverse effect. Nominal NOEL = 50 ppm (decreased body weight at mid and high doses; hepatocellular carcinoma, adenoma and hyperplasia were observed in females at the high dose. Other dose-related non-neoplastic changes in males and females were observed primarily at mid- and high-doses. Microscopic lung changes were observed at all dose levels in both sexes but were not well defined ("pigmented alveolar macrophages," “eosinophilic foreign bodies”). Originally reviewed as unacceptable by McGee, 4/29/86 (no individual data on food consumption; no individual clinical observations; no statistical analysis of tumor data) and not upgradeable, based on lung findings at all treatment levels. In view of the uncertain nature of the lesions and the consideration of this study as an oncogenicity study, it may be upgradeable with submission of the missing data. DPR has received and reviewed the requested information (204 069674), and the study is upgraded to ACCEPTABLE. M. Silva, 10/28/88.

EPA one-liner (Partial excerpt): (NOEL not indicated), Increased incidence of hepatocellular carcinomas and hyperplastic nodules in females at high dose level, dose-related non-neoplastic liver and lung injuries in male and females, decreased weight gain at the high dose level in male and female; core grade--minimum.


085 973194 Interim report of record 037729. (Reviewed by J. Wong, 5/16/85, as unacceptable with a possible adverse oncogenic and/or chronic effect.)

067 973193 Interim report for record 037729.

128 016928 Supplement to record 037729 -- discussion of hepatocarcinomas in female mice.
128  016929 Historical histopathology data for record 037729.

161  Rebuttal of 11/20/86 to DPR review of 037729.

161  050991 Homogeneity of diet mixing for 037729.

Letter of 5/5/88. Chevron has committed to supply individual data as requested.

015  973191 Invalid IBT study, 3/7/73.

REPRODUCTION, RAT

148  037738 “Effect of Technical Re-12420 (Orthene) on Reproductive Function of Multiple Generations in the Rat.” (Huntingdon, 4/18/83). Acephate technical (92.8%, SX-1032) fed in the diet at 0, 50, 150 or 500 ppm for a three generation, two litter/generation study with CrL:cobs CD(SD)BR rats, 12 males and 24 females per group. There was reduced fertility, especially in males, reduced pup viability. Parental (maternal) MTD = 500 ppm. Fertility and viability NOEL not determined due to fact that noted effects had a similar frequency at low and high doses but not at mid dose. UNACCEPTABLE (inadequate number of gravid animals per group, incomplete histopathology, other studies conducted in same animal rooms, no standardization of litter size, no historical control data presented). Not upgradeable. A repeat study following guidelines is recommended. McGee, 8/1/86.

No EPA one-liner.

110  973202 Supplement to record 037738--Statistical analysis report.

110  973204 Less complete version of record 037738 (Reviewed by J. Wong, 5/22/85, as unacceptable due to insufficient but with a possible adverse effect identified in the report as submitted by registrant).

** 182  060979 “Two-Generation (Two Litter) Reproduction Study in Rats with Chevron Acephate Technical.” (Argus Research Laboratories: 303005, 4/3/87) Chevron acephate technical, 98.5%, was fed in the diet to Crl:COBS CD (SD) BR rats, 30/sex/group, at 0, 25, 50 or 500 ppm for two generations, 2 litters/generation, and one litter in the third generation. Parental NOEL = 50 ppm (soft/liquid feces), Reproductive NOEL = 50 ppm (reduced litter size and postnatal survival). This study was conducted primarily to address the effects reported in an earlier study (DPR # 37738) in which a NOEL was not established. This present study does demonstrate a NOEL for both viability and fertility. ACCEPTABLE. Shimer, 11/24/87, J. Gee, 12/30/87.

No EPA one-liner.

209  072152 “Two-Generation (Two Litter) Reproduction Study in Rats with Chevron Acephate Technical.” This volume contains a final revision of the definitive rat reproduction study (182 060979). Two changes were made: 1. post natal survival at 25 ppm for first generation F1a litter was changed to not be statistically lower than the value for the control. 2. # of pups dying Days 1-4 at 500 ppm for first generation F1a litter was changed to not be statistically significant when
compared to control. The data were accompanied by a summary letter. The changes did not alter the outcome of the study, nor did it alter its acceptability. D. Shimer & M. Silva, 3/30/90.

014  973205 Invalid IBT study, 1/10/73.

Summary: The study conducted at Huntingdon, DPR Record #037738, identified a possible adverse reproductive effect on fertility, especially in males, and decreased pup viability at 50 and 500 ppm. These effects were not confirmed in the later study (DPR Record #060979) at 50 ppm with reproductive effects seen only at 500 ppm in the presence of parental effects. The collective data are adequate to fulfill the requirement with the reproductive NOEL at 50 ppm and no effect seen without some parental effects. The overall conclusion is that acephate does not cause adverse reproductive effects. Gee, 1/5/88.

REPRODUCTION, CHICKEN

014  973207 Invalid IBT study on chicken; not a SB950 test species.

111  973081 Reference to record #973207.

TERATOLOGY, RAT

**  219, 230  074315, 088434 “Oral Teratogenicity and Developmental Toxicity Study in Rats with Chevron Acephate Technical.” (Argus Research Laboratories, Study No. 303-008, 2-13-89). Acephate technical (Lot #: SX-1725; purity = 99.5%, or Lot #: SX-1102; purity = 98.7%) was administered to mated Crl:CD®(SD)BR rats (25/dose) by gavage on days 6 - 15 of presumed gestation (presence of vaginal sperm or copulatory plug = day 0 of gestation) at 0, 5, 20 or 75 mg/kg/day. Maternal NOEL = 5 mg/kg (increase in tremors, decrease in motor activity, body weight and food consumption). Developmental NOEL = 20 mg/kg (decreased fetal body weight, and delay in ossification of hindpaw phalanges--historical controls for malformations and alterations were provided in the report). No adverse effects. Volume/record # 230/088434 contained an analysis of dosing solution. ACCEPTABLE. D. Shimer & M. Silva, 4/2/90.

012  973200 “Teratogenic Study With Orthene Technical in Albino Rats.” (IBT No. B190, 9/17/71). Acephate (approximately 90%, lot SX-284) given by oral gavage at 0, 25, 100 or 200 mg/kg/day on days 6-15 of gestation, 17-21 pregnant females/group. There was a slight increase in resorption rate at the high dose, dose related decreases in maternal body weight gain, maternal toxicity considered contributory to resorption rate at 200 mg/kg and no developmental toxicity directly attributable to test article. UNACCEPTABLE (no individual animal data presented, dose level not justified, no analysis of dosing solutions, statistical analysis not provided). Not upgradeable. Purity of test article from 165, 063368, which contains the results of a 1978 audit of the raw data compared with the report. The audit found that the control data were from another study and no data were sent to the sponsor of the acephate study. Note: Initial review by J. Wong, 5/13/85 indicated a possible adverse effect. Review by D. McGee, 5/6/86, and J. Parker found no effect without maternal toxicity. Gee, 1/7/88.
EPA one-liner: teratogenic NOEL > 200 mg/kg, slightly more resorption sites per female at 200 mg/Kg than in controls, less wt. gain at 100 mg/Kg level and 200 mg/Kg by females during gestation; core grade--minimum.

Rebuttal of 11/20/86 to DPR review of 973200.

TERATOLOGY, RABBIT

** 146  037733  “Teratology Study in Rabbits (Technical RE 12420, Orthene).”  (IRDC, 11/13/80).  Acephate (92.8%, SX-1032) given by oral gavage at 0, 1, 3 or 10 mg/kg/day on days 6-27 of gestation, not adjusted for purity, with 16 per group.  No significant developmental effects.  Slight maternal toxicity at high dose.  Developmental NOEL = >10 mg/kg, maternal NOEL = 3 mg/kg.  Initially reviewed as unacceptable (McGee, 5/2/86) based on incomplete necropsy data, no analysis of dosing solutions and fetuses which aborted days 25 and 27 were not examined for malformations but study possibly upgradeable.  Submission of record #061138 provides copies of records for preparation of the daily dosing solutions and 058219 - 058222 address stability in neutral aqueous solutions.  ACCEPTABLE (see Medical Toxicology Response of 6/2/88).  J. Gee, 12/31/87, Davis 6/2/88.

EPA one-liner:  Teratogenic NOEL => 10 mg/Kg, fetotoxic NOEL => 10 mg/Kg, maternal toxic NOEL = 3 mg/Kg; core grade--guideline.

146  037734  Positive control data for 037733 with 6-aminonicotinamidate.

171  061138, 058219-058222  Stability data for 037733.
067  973196  Less complete version of record 037733. (Reviewed by J. Wong, 5/22/85, with insufficient information for evaluation.)

067  973197  Pilot study for record 037733.

161  050990  Supplement to 37733.  Individual data for does #4511 and 4518.

161  Rebuttal of 11/20/86 to DPR review of 037733.

Rebuttal letter of 5/5/88.  Reconsideration of all information provided led to upgrading the study to acceptable.  Because acephate is quite stable under the conditions of the study, because dosing solutions were prepared daily, and because IRDC notebook pages on dosing solution preparation were provided, the lack of dosing solution analysis was not considered to invalidate the study.  Davis 6/2/88.

014  973198  Invalid IBT study, 4/14/72.
Bacterial Systems

** 101 973209  “Potential of Technical and Analytical Grade Orthene to Mutate Histidine Deficient Strains of Salmonella typhimurium (S-1202).” (Chevron, 11/28/77). Acephate (92.41%, SX-941) was tested at 0.001 to 10 μg/plate with Salmonella strain TA100 and at 1, 2 and 10 μg/plate with strains TA 98 and 1537, with and without rat liver S9. There were 2 plates/dose level. Results indicated weak mutagenic activity in TA 100 with and without activation. ACCEPTABLE by J. Wong. Comments by J. Gee, 9/30/86. This study included only 3 of the 4 strains listed in the guidelines. It did, however, include high amounts of acephate and repeat trials to confirm the weak effect with TA100 with the mutants per plate increasing in a concentration dependent manner but not reaching twice the spontaneous rate even at 10 ug/plate. Alone, this effect in one strain, especially TA100, would not be conclusive as to the genotoxic effect of acephate. Taken together, however, with other studies listed below, the positive effect needs evaluation. Wong, 5/20/85, Gee, 9/30/86.

EPA one-liner: Weakly positive with S. typhimurium strain TA 100 and negative with TA 98 and TA1537 strains, with or without metabolic activation; core grade--acceptable.

113 028970 “In vitro Microbiological Mutagenicity and Unscheduled DNA Synthesis Studies of Eighteen Pesticides: Excerpt for Acephate on Reverse Mutation with Salmonella typhimurium and Escherichia coli.” (SRI, 10/79). Acephate (93.5%, Lot SX-7562) was tested at 0, 1, 10, 50, 100, 500, and 1000 ug/plate (Exp. 1), 10 to 5000 ug/plate (Exp. 2), 1000 to 10,000 ug/plate (Exp. 3) and 2500 to 10,000 ug/plate (Exp. 4), with and without rat liver S9 on Salmonella strains TA98, TA100, TA1535, TA1537, and TA1538. Results indicated acephate was weakly mutagenic in TA 100. UNACCEPTABLE (only a single plating/dose level, statistical treatment of data not evident). Probably not upgradeable. Wong, 5/17/85.

EPA one-liner: Positive results on TA 98 and 100 at 5000 ug/plate and above; core grade--acceptable.

149 039417 More complete version of record 028970. Some of the objections of the initial review by J. Wong still stand [J. Gee, 9/30/86]. The data gap is filled by other studies.

113 973217 “Further Mutagenicity Studies on Pesticides (Bacterial Reversion Assay - S. typhimurium and E. coli.” (Inst. Environ. Tox.-Japan, 5/18/82). Publ. in Mutation Res. 116: 185-216 (1983) – survey of 228 pesticides in Ames test on Salmonella strains TA 98, 100, 1537 and 1538. Acephate (no purity stated) was tested at 0 to 50 μg/plate. No data - results given as “+” for TA100 and E. coli; an increase reversion frequency above 5 mg/plate with TA100; UNACCEPTABLE. Wong, 5/20/85.

147 973214 “Salmonella/Mammalian Microsome Mutagenicity Test (Ames Test) with six Samples of Chevron Acephate Technical and Purified (SX-911, SX-941, SX-978, SX-984, SX-986, SX-988) S. typhimurium Chevron, 12/82). Acephate (6 lots, SX-911, -941, -978, -984, -988 and -986) tested at 0 - 50 μg/plate on Salmonella strain TA100 in one trial, no activation. All lots were weakly mutagenic in TA100. Incomplete, UNACCEPTABLE (no metabolic activation, no repeat trials, missing data, no individual plate counts, number of platings not clear). Not upgradeable. Wong, 5/16/85, Gee, 5/12/86.
EPA one-liner: All six batches of acephate tested positive on strain TA100; core grade--supplementary.

147 016927 “Salmonella/Mammalian Microsome Mutagenicity Test (Ames Test) with Seven Samples of Chevron Acephate Technical (SX-257, SX-284, SX-357, SX-941, SX-978, SX-979 and Acetamide SX-976).” (Chevron, 12/82). Acephate (8 lots--85 to 100%, SX-257, -284, -357, -911, -941, -976, -978, -979) were tested at 0 - 50 μg/plate on Salmonella strains TA98, 100 and 1537 without activation, one trial, no individual plate counts. Seven of 8 lots weakly positive in TA100. UNACCEPTABLE (should TA100 read TA1537 in Table 2(?), no repeat trial, number of platings not clear, no individual plate counts, no activation included), Not upgradeable. Gee, 5/12/86.

EPA one-liner: 7 of 8 batches of acephate tested positive on strain TA 100; core grade--supplementary.

128 016927 Duplicate of 147 016927 without the analytical pages.

113 973213 Unrevised version of study identified as record 016927.


EPA one-liner: Weakly mutagenic with (5000 μg/plate) and without (6000 μg/plate) metabolic activation; core grade--acceptable.

149 039417 More complete version of record 028970. (J. Gee, 9/30/86: Some of the objections of the initial review still stand.)

Insect Systems

113 973218 “Mutagenesis Screening of Pesticides Using Drosophila Sex Linked Recessive Lethal: Chromosome Loss, Rearrangement and Nondisjunction.” (WARF, 2/81). Acephate (purity not stated, no lot number) was tested at 10 ppm with 14 other pesticides in sex-linked recessive lethal assay on Drosophila melanogaster. No adverse effect reported. UNACCEPTABLE (report missing pages-including tables with acephate results). Wong, 5/17/85.

EPA one-liner: negative at 10 ppm; core grade--inadequate.
Mammalian Systems

113 973216  "Evaluation of Mutagenic Potential of Acephate Employing the L5178 TK +/- Mouse Lymphoma Assay (Forward Mutation)."  (SRI, 9/80).  Acephate (purity not indicated, lot SX-734 -- 93.5% in 113 973225) was tested at 10 levels between 1000-5000 ug/ml +/- rat liver S9 on mouse lymphoma cells (L5178Y).  Duplicate platings/dose level with 4 hour exposure, 2-day expression time with a repeat trial.  Increased mutation frequency at TK locus without S9 at 1000-5000 ug/ml and increased mutation frequency with S9 at 2000-5000 ug/ml.  UNACCEPTABLE (need positive characterization of test article), Upgradeable.  Wong, 5/17/85, Gee, 10/2/86.

EPA one-liner: Positive effects at 2000 ug/ml and above +S9 and positive effects at 1000 ug/ml and above -S9; core grade--acceptable.

** 101 973210  "L5178Y TK+/- Mouse Lymphoma Mutagenesis Assay with Chevron Acephate Technical (SX-1102)."  (Microbiological Associates, 8/2/82).  Acephate (technical, lot SX-1102, 98.7%) was tested at 2429, 3071, 3714, 4357 and 5000 ug/ml +/- rat liver S9 on mouse lymphoma cells (L5178Y).  There were duplicate cultures/dose level, 4 hour exposure, 48 hr expression time.  A dose-dependent increase in mutation frequency over entire dose range +/- S9.  ACCEPTABLE.  Wong, 5/21/85.

EPA one-liner: Moderately positive, with and without S9, core grade--acceptable.

** 101 973211  "Mouse Lymphoma Mutagenesis Assay with Chevron Acephate Technical (SX-762)."  (Microbiological Associates, 8/2/82).  Acephate (93.5%, lot SX-762) tested at 2429, 3071, 3714, 4357 and 5000 ug/ml +/- rat liver S9 on mouse lymphoma cells (L5178Y); 6 platings/dose level, 4 hour exposure and 48 hr expression time.  Identical to study identified as record #97310 except a different lot of test article used.  Dose-dependent increase in mutation frequency at TK locus over entire dose range +/- S9.  ACCEPTABLE.  Wong, 5/21/85.

EPA one-liner: Moderately positive, with and without S9, core grade--acceptable.

167 058112, 058113  "Evaluation of Chevron Acephate Technical in the Mouse Somatic Cell Mutation Assay."  (Hazleton, Project No. 2107-141, 10-86)  Acephate technical, batch SX-1102, 98.7%, was tested in the mouse somatic cell spot test.  854 females were tested by feeding 0, 50, 200, 600 or 800 ppm acephate in the diet on days 8.5 to 12.5 of gestation, ethylnitrosourea was the positive control given at day 10.5, ip.  On days 14 and 28 of lactation pups were examined for recessive coat spots.  Toxic effects observed in females at 600 and 800 ppm include lacrimation, tremors, and staggered gait.  The positive control was functional, no increase in recessive coat spots in acephate treated litters.  UNACCEPTABLE (route of administration, no good evidence fetuses were exposed to test material) Shimer and J. Gee, 1/4/88.

Summary: Multiple reports on file with DPR contain evidence that acephate is weakly mutagenic/genotoxic in both bacterial and mammalian tests in vitro. A number of lots of acephate have been tested with Salmonella typhimurium strains with positive effects especially in strain TA100 with and without metabolic activation at high concentrations (in the mg/plate range). With mammalian cells, three reports are on file showing positive mutagenic effects in mouse lymphoma (L5178Y) in two acceptable studies and one, which is upgradeable. Three different lots were used in the mg/ml range with and without S9 activation. It should be noted
that TA100 is often considered the most sensitive strain of *Salmonella* and L5178Y has been shown to give a higher percent of “false positives” for chemicals than, for instance, Chinese hamster cells. Some of the animal data, however, on which the evaluation of a chemical as a carcinogen/noncarcinogen is based, are not adequate, putting the “false positive” rating in some question. The fact that other test types are also positive (see below) and the reproducibility of the two tests under discussion above lend weight to the weak genotoxic effect. The *in vivo* mouse somatic cell mutation assay was not acceptable largely because there was no evidence presented to verify that the test article had crossed the placenta. Gee, 10/3/86 and 1/5/88.

**CHROMOSOME EFFECTS**

112 028968, 028969 “Orthene Technical: Cholinesterase Inhibition and Cytogenetics in the Monkey, Final Report.” (LSR, 1/21/83). Acephate (98.7%, lot SX-1102) was tested for SCE (028968) and chromosome aberrations (028969) at 0 and 2.5 mg/kg only by gavage for 20 days. Peripheral lymphocytes of monkey (*Macaca fascicularis*) were stimulated with phytohemagglutinin. Cells arrested in mitosis after 45 hours were incubated for 3 hours, then harvested. 1/sex/group for SCE and 1/sex/group for chromosome aberrations - lymphocytes for SCE from same animals were incubated as for aberrations but with BUDR added and incubation extended to 72 hours total. Cholinesterase inhibition was demonstrated, but no mutagenic effects noted. UNACCEPTABLE (no data included in the report), Not upgradeable. Wong, 5/21/85. EPA one-liner: Negative at 2.5 mg/kg or body weight (only level tested) after 20 days of dosing by gavage; core grade--acceptable as supplementary.

113 973221 “Micronucleus Test on Acephate-Mice.” (SRI, 3/10/80). Acephate (purity not reported but written notation of 96.6% for lot SX-734) given by gavage twice over 24 hrs at 0, 75, 150 and 300 mg/Kg to mice for micronucleus assay; justification of dose based on an oral LD50 in mice of 361 mg/kg; 24 males/group, 8 in positive control group; sampling from 8 males at 48, 72 and 96 hrs post-treatment; 500 PCE's/animal; no fatalities; no genotoxic effect reported; UNACCEPTABLE (only males tested with no justification, too few PCE's/animal, husbandry problem suggested with weight loss in controls due to “unreachable water” -- only evidence of toxicity at high dose is based on weight loss). Possibly upgradeable. Wong, 5/20/85. EPA one-liner: Not mutagenic according to this test; core grade--minimum.

** 101 973220 “Dominant Lethal Study of Acephate Technical (SX-1102)” (Chevron, 6/11/82). Acephate (99%, lot SX-1102) given in the diet for five days at 0, 50, 500 and 1000 ppm to CD-1 mice for a dominant-lethal assay; 12 males and 190 females/group, 2 females:male for 8 weeks of mating, positive control included; no adverse effect noted. ACCEPTABLE. Wong, 5/21/85. EPA one-liner: Negative, when fed to CD-1 male mice; core grade--acceptable.

012 973219 Invalid IBT study.

** 101 973212 “Cytogenetics Study in Mice Acephate Technical (SX-1102).” (E G & G Mason Res. Inst., 8-27-82) Acephate (98.7%, lot SX-1102) given by oral gavage in a single dose at 0, 11.2, 37.3 and 112 mg/Kg to Swiss white mice for a bone marrow cytogenetic assay; 4/sex/group, positive control included; clinical signs of toxicity reported; dose selection based on
acute toxicity studies included with the report; no adverse effect indicated. ACCEPTABLE.
Wong, 5/21/85.
EPA one-liner: Negative at 112 mg/kg; core grade--acceptable.

** 113 973224 “Evaluation of the Effect of Acephate on Sister Chromatid Exchange
Frequencies in Cultured Chinese Hamster Ovary Cells.” (SRI, 6/80). Acephate (purity not
indicated, lot SX-734 with purity given as 93.5% in report 113 973225) tested at 0, 125, 250,
500, 1000 or 2000 ug/ml for 21.5 hours without S9 and at 0, 312.5, 625, 1250, 2500 or 5000
ug/ml for 2 hours with rat liver S9 activation; CHO cells in culture for SCE assay; 2
platings/dose level, positive controls included; increase frequency of SCE at 500 ug/ml without
S9 and at 5000 +S9. UNACCEPTABLE (test article not characterized) was the initial review by
Wong. In view of the fact that the purity of this lot is contained in another report submitted at
the same time, the deficiency is not considered grounds for rejecting an otherwise adequate study
-- Gee. Wong, 5/20/85, Gee, 10/1/86.
EPA one-liner: Positive results without metabolic activation above 1000 ug/ml, positive results
with metabolic activation at 5000 ug/ml; core grade--acceptable.

112 973222 “Mutagenicity Evaluation of Chevron Acephate Technical SX-1102 in the Sister
Chromatid Exchange Assay in vivo in Mouse Bone Marrow.” (Litton, 1/83). Acephate
的技术, purity not stated, lot SX-1102 [purity of this lot from other reports is 99%] given by
oral gavage in a single dose at 0, 29 or 96 mg/Kg to CD-1 mice for SCE assay; 5/sex/group,
positive controls included; no adverse effect indicated. UNACCEPTABLE (test article not
positively characterized, inadequate number of dosing levels, report incomplete--missing
appendices and tables, number of animals not indicated). Not upgradeable. Wong, 5/21/85.
EPA one-liner: Negative at 96 mg/kg; core grade--acceptable as supplementary.

158 045233 More complete version of record #973222. J Gee, 9/29/86. Study is still
unacceptable based on inadequate dose selection justification and lack of toxicity, no individual
values and no spindle inhibitor given so inadequate number of mitotic cells were available in
some groups. The reason for not evaluating slides from the 289 mg/kg group used in the
preliminary study and also in the main study from dosing error is not adequate in view of the
lack of maximal tolerated dose at 96 mg/kg.

Summary: In vivo chromosome studies for dominant lethal and bone marrow chromosomal
aberration formation in CD-1 and Swiss mice respectively, were both acceptable and negative
for observable effects. A study for micronuclei formation in polychromatic erythrocytes, in male
mice only, also showed no response to acephate but this was not an acceptable report as
submitted. Another study with PHA-stimulated peripheral lymphocytes from monkeys exposed
for 20 days in vivo showed no observable effect for sister chromatid exchange or chromosomal
aberrations. An in vitro study with Chinese hamster ovary cells did show an increase in SCE's.
This was an acceptable test. Another study on in vivo sister chromatid exchange in CD-1 mice
was negative but the high dose was questionable as adequate for the test. None of the in vivo
reports included good evidence that the bone marrow was exposed to a meaningful dose unlike
in vitro tests where exposures of the target cells are more readily controlled. Clinical toxicity
other than that to bone marrow precluded higher doses in some studies in mice (e.g., #973212).
The conclusion is that there is evidence in vitro for a possible genotoxic effect. Gee, 10/3/86 and
1/5/88.
DNA DAMAGE/REPAIR

113 973225  “Differential Toxicity Assays of Nineteen Pesticides Using Salmonella typhimurium strains (DNA Damage/Repair).”  (SRI, 2/81).  Acephate (93.5%, SX-734) tested at 0, 1 and 5 mg/disk on Salmonella strains SL 4525 (rec+), SL 4700 (rec-), TA1978 (uvrB+) and TA1538 (uvrB-) in a spot test for differential toxicity without metabolic activation; 2 platings/dose level, positive controls included; two trials; no adverse effects reported in first trial but differential growth reported with SL (rec) strains in second trial: rec+ with 9 mm and rec- with 12 mm zone of inhibition (6mm disk); UNACCEPTABLE (no activation included). Review by Gee identifies a possible adverse effect. Wong, 5/20/85, Gee, 10/1/86. EPA one-liner: Negative up to 5 mg; core grade--acceptable.

113 028972  “In vitro Microbiological Mutagenicity and Unscheduled DNA Synthesis Studies of Eighteen Pesticides: Excerpt for Acephate on Differential Toxicology in Escherichia coli and Bacillus subtilis.”  (SRI, 10-79)  Acephate (93.5%, lot SC-7562) tested at 0.01, 0.10, 1.0 and 5.0 mg/disc/plate on E. coli strain W3110/p3478 and B. subtilis strains H17/M45 in a spot test (damage/repair); 1 plate/dose level, no repeat trial; no adverse effect indicated. UNACCEPTABLE (single plating and no repeat trial, no activation.) Reason why B. subtilis H17/M45 (rec +/-) did not show differential effect as did Salmonella (#973225) is not clear. Wong, 5/17/85. EPA one-liner: negative; core grade -- unacceptable.

149 039419  More complete version of record 028972. Gee, 10/1/86. The objections in the initial review stand.

113 028971  “In vitro Microbiological Mutagenicity and Unscheduled DNA Synthesis Studies of Eighteen Pesticides: Excerpt for Acephate on Mitotic Recombination with Saccharomyces cerevisiae.”  (SRI, 10/79).  Acephate (93.5%, lot SX-7562) tested at 0, 0.1, 0.5, 1.0 and 5.0 % (trial 1) and at 1, 2, 4 or 5% (trial 2) +/- S9 on S. cerevisiae strain D3 in a mitotic recombination assay; incubated for 4 hours on a roller drum, then diluted and plated on 5 plates for survivors x 10^-5 and 3 plates for mitotic recombinants x 10^-3; positive effects at 1% and above with and without metabolic activation. UNACCEPTABLE (dose selection not justified with marginal cytotoxicity demonstrated, no individual plate counts and no statistical analysis reported, use of DMSO as solvent is not recommended.) Wong, 5/17/85. EPA one-liner: Positive at 1% and above; core grade--acceptable.

149 039418  More complete version of record 028971. Gee, 10/1/86. Evaluation stands.

113 973215  “Orthene Technical: Cholinesterase Inhibition and Mitotic Gene Mutation, and Reverse Mutation with S. cerevisiae D7 for 7 Pesticides - Orthene.”  (SRI, 6/80).  Acephate (93.5%, lot SX-734) tested at 0, 1, 2, 3, 4 and 5% +/- rat liver S9 on S. cerevisiae strain D7 (diploid) in mitotic crossing over and gene conversion assays; repeat test using 3, 3.5, 4, 4.5 and 5%; incubated for 4 hours, then diluted and plated; with S9, an increase in mitotic crossing over and reverse mutation at 2% and above-- increased frequency of gene conversion at 1% and above; without S9, an increase in frequency of crossing over, reverse mutation and gene conversion at 1% and above. UNACCEPTABLE (number of plates/group not clear, no rationale for dosing levels, individual plate data not included, methods of statistical treatment not clear). Possibly upgradeable. Wong, 5/16/85.
EPA one-liner: Positive for crossing over, gene conversion and reverse mutation at 1% and above without metabolic activation, positive for gene conversion at 1% and above, positive for crossing over and reverse mutation at 2% and above with metabolic activation; core grade--acceptable.

** 113 028973  “In vitro Microbiological Mutagenicity and Unscheduled DNA Synthesis Studies of Eighteen Pesticides: Excerpt for Acephate on Unscheduled DNA Synthesis.” (SRI, 10/79). Acephate (93.5%, lot SX-734) tested at 0.1 to 72 ug/ml without S9 (Exp. #1), 125 to 2000 ug/ml without S9 (Exp. #2), 0.1 to 1000 ug/ml with rat liver S9 (Exp. #3) and 250 to 4000 ug/ml (Exp. #4) with contact-inhibited WI-38 human fibroblasts in UDS assay; 3 hour exposure without activation and 1 hour with activation; hydroxyurea to block semiconservative DNA synthesis; DNA was extracted, DNA determined by diphenylamine reaction and tritium quantitated by liquid scintillation counting; in the absence of activation, slight increase in UDS at and above 1000 ug/ml. Initial review by Wong indicated an incomplete report with no protocol submitted. 149 039428 contains the full document making the study ACCEPTABLE with an adverse, genotoxic effect (Gee, 10/1/86). Wong, 5/17/85,

EPA one-liner: Positive response without metabolic activation at 1000 ug/ml and above; core grade--acceptable.

149 039420  More complete version of record 028973. Gee, 10/1/86. See above.

Summary: Comparison of differential toxicity in repair proficient versus repair deficient strains of Salmonella suggest an adverse effect on viability of cells with a defective recombinant repair pathway (rec-), while the UV-repair deficient strain (uvrB-) grew approximately the same as the uvrB+ strain. Bacillus subtilis rec+/- strains, however, did not show any difference in growth for reasons that are not known. On the other hand, Saccharomyces cerevisiae D3 and D7 both showed increased mitotic recombination, mitotic crossing-over and gene conversion with exposure to acephate, lending support to the data with Salmonella. In these tests, DNA damage occurs of a type, which is repaired by DNA recombination. When a cell cannot perform this function, it is killed reproductively. In proficient strains, repair occurs, allowing for survival or, in Saccharomyces, enhancing mitotic crossing over, which is essentially a test of repair. In addition, there was a slight increase in unscheduled DNA synthesis in mammalian cells, substantiating the results in microbial systems. Gee, 10/3/86 and 1/5/88.

SUMMARY OF GENOTOXICITY STUDIES: Taken altogether, the studies in the three areas indicate the in vitro tests reported to DPR were more sensitive than the in vivo genotoxicity studies submitted or acephate is non-mutagenic in vivo. The possibility of in vivo effects should not, however, be dismissed 1) because correlation of in vitro to in vivo effects is not well understood and 2) in vivo tests in other areas on file suggest adverse oncogenic effects. Full assessment of these effects cannot be made unless adequate in vivo studies in the area of genotoxicity are available. The data requirements are fulfilled by the in vitro studies. Gee, 10/3/86 and 1/5/88.
NEUROTOXICITY (INCLUDING CHOLINESTERASE INHIBITION STUDIES)

** 151 039603, 039602 “Acute Delayed Neurotoxic Study in Chickens with Chevron Acephate Technical Final Report and Addendum.” (Wildlife International, 10/18/85). Acephate (98%) at 785 mg/Kg, re-dosed after 21 days, 5 mg/kg atropine to protect at dosing with additional atropine given over 21 hours; 6 hens in control groups and 12 in treatment group; TOPC positive control; no delayed neurotoxicity note. ACCEPTABLE. McGee, 4/21/86.

** 067 973171 “Studies on Acute Delayed Neurotoxicity of Orthene (Chickens).” (Bozo Research Center-Japan, 11/79). Acephate (98.9%) at 375 mg/Kg by gavage, one dosing, 5 mg/kg atropine to protect; 12 hens in control groups and 24 in treatment group; TOPC positive control; no delayed neurotoxicity noted. ACCEPTABLE. Wong, 5/22/85.

EPA one-liner: Negative, but insufficient; core grade-supplementary.

015 973172 Invalid IBT study, 1/20/72.

** 108-286 153408 “Subchronic (13-Week) Neurotoxicity Study of ORTHENE Technical in Rats.” (M.D. Nemec; WIL Research Laboratories, Inc., Ashland, OH; Project ID No. WIL-194014; 1/16/97) Thirty Sprague-Dawley rats/sex/group were dosed orally in the diet with 0, 5, 50 or 700 ppm of ORTHENE Technical (lot no. SX1725, purity: 99.0%) for up to 13 weeks ((M): 0, 0.33, 3.31, 48.63 mg/kg/day, (F) 0, 0.41, 3.95, 58.27 mg/kg/day). There were no treatment-related effects upon mean body weights or food consumption. Although some of the FOB parameters and motor activity measurements for the treated animals were statistically different from that of the control group, there was no consistent pattern of effect noted over the course of the study. The mean cholinesterase (ChE) activity levels for plasma were lower than that of the control at 3 weeks for the 50 ppm males and females (p<0.05 or p<0.01) and at 3, 7 and 13 weeks for the 700 ppm males and females (p<0.01). The mean red blood cell activity levels were less at 3, 7 and 13 weeks for the 700 ppm males and females (p<0.01). The mean red blood cell activity levels were less at 3, 7 and 13 weeks for the 700 ppm males and females (p<0.01). In the 6 subregions of the brain for which ChE activity was assayed, the activity levels were less than that of the control at 50 ppm and above for all of the regions at least twice for the 3 time points assayed (p<0.1). The mean percent of control activity for the 50 ppm males ranged from 50.6% in the cortex (week 13) to 75.8% in the cerebellum (week 13). For the 50 ppm females, the percent of control activity ranged from 45.4% in the hippocampus (week 13) to 81.5% in the brainstem (week 3). For the 5 ppm treatment group males, ChE activity was reduced in the hippocampus (week 3, p<0.01, 86.1% of control), midbrain (weeks 3, 7, 13, p<0.01, 85.0 to 90.6%), cerebellum (weeks 3, 7, 13, p<0.01, 89.1%), and cortex (weeks 3, 7, 13, p<0.01, 82.4 to 89.9%). Similarly, for the 5 ppm females, ChE activity was less in the hippocampus (week 13, p<0.01, 71.6% of control), olfactory lobe (weeks 7, 13, p<0.05, 75.7, 82.2%), midbrain (weeks 3, 7, 13, p<0.01, 80.9 to 91.0%), cerebellum (week 7, p<0.1, 83.9%) and cortex (week 13, p<0.01, 86.2%). No treatment-related effects were noted in the histopathological examination. Possible adverse effect: significant brain ChE inhibition; NOEL (Clinical Signs): (M/F) 700 ppm (M): 48.63 mg/kg/day, (F): 58.27 mg/kg/day) (based upon the lack of treatment effects in the FOB determinations for the 700 ppm group); NOEL (ChE Inhibition): < 5 ppm ((M): < 0.33 mg/kg/day, (F) < 0.41 mg/kg/day) (based upon significant brain ChE inhibition at 5 ppm). Study acceptable. (Moore, 2/6/02)

Thirty Sprague-Dawley rats/sex/group were dosed by oral gavage with 0, 10, 100 or 500 mg/kg of Orthene Technical (lot no. SX1725; purity: 99.0%). Twelve animals/sex/group were evaluated in the Functional Observational Battery (FOB) and for locomotor activity as well as in the neuropathology examination. The other 18 animals/sex/group were euthanized for cholinesterase (ChE) activity evaluation, 6 animals/sex/group at 2.5 hours and 7 and 14 days post-dose. No animals died as a result of the treatment. The mean body weight for the males in the 500 mg/kg group was less than that of the controls at 7 days post-dose (p<0.05). Clinical signs included whole body tremors, repetitive movement of the mouth, tremors of the forelimbs and/or hindlimbs, and alterations in the posture/gait of the animals in the 100 and 500 mg/kg groups in a dose-related manner. The earliest observation of these signs was at 30 minutes and the time to peak effect was between 2 and 2.5 hours and persisted up to 8 hours post-dose in the high dose group. The signs were no longer present by the next day. Salivation, lacrimation and chromodaccryorrhea was observed only in the 500 mg/kg animals. In the FOB, at 2.5 hours post-dose, the 100 and 500 mg/kg animals exhibited in a dose-related manner, abnormal posture, whole body tremors which ranged from slight to extremely coarse, slightly impaired to totally impaired mobility, walking on tiptoes to ataxia, decreased arousal and rearing, diminished response to a tail pinch, impaired righting reflex, and reduced body temperature. In addition, the high dose animals exhibited signs of lacrimation, salivation, poor grooming, diminished startle, touch and approach responses and catalepsy. The males in the high dose group had no pupillary response. The hindlimb extensor strength was reduced for the males in both the 100 and 500 mg/kg groups and the females in the 500 mg/kg group. The fore and hindlimb grip strength for the high dose males was reduced from that of the controls (p<0.01 and p<0.05, respectively). The rotorod performance was affected in all of the male treatment groups (p<0.01) and for the high dose females (p<0.01). In the motor activity evaluation, total activity and ambulatory activity counts were reduced for the animals in the 100 and 500 mg/kg groups. All of these parameters had returned to normal by day 7. In the ChE activity determinations, all of the treatment groups for both sexes exhibited reduced activity levels in the plasma, red blood cells and subregions of the brain at 2.5 hours post-dose (p<0.01). At 7 days post-dose, reduced activity was still evident in the following tissues: hippocampus, females, 500 mg/kg; midbrain, males, 500 mg/kg, females, 500 mg/kg; brainstem, males and females, 500 mg/kg; cerebellum, males and females, 500 mg/kg; cortex, males, 500 mg/kg, females, 10, 100, 500 mg/kg (p<0.05 or p<0.01). At 14 days, activity was reduced in the red blood cells and the midbrain of the 500 mg/kg males (p<0.05 and p<0.01, respectively). No treatment related lesions were evident in the neuropathology examination. Possible Adverse effect: extensive neurotoxic signs; NOEL(clinical signs) (M/F): 10 mg/kg (based upon the clinical signs manifested by the 100 mg/kg treatment animals); NOEL (cholinesterase inhibition): < 10 mg/kg (based upon ChE inhibition evident in the plasma, red blood cells and subregions of the brain of the 10 mg/kg treatment group); Study acceptable. (Moore, 10/16/01)

108-284 153406 “Range-Finding Acute Study of Orthene® Technical in Rats” (M.D. Nemec; WIL Research Laboratories, Inc., Ashland, OH; Project No. WIL-194015; 4/27/95) Two Sprague-Dawley rats/sex/group were dosed by oral gavage with 0, 5, 25, 125 or 500 mg/kg of Orthene® Technical (batch no. SX 1725, purity: 99.4%) in Phase I. In Phase II, five females/group were dosed orally with 0, 0.5, 2.5 or 5 mg/kg of the test material. In Phase I, animals received detailed clinical examinations at 15 and 30 minutes and 1, 2 and 2.5 hours post-dose. In Phase II, the animals were examined at the time of euthanization, 2.5 hours post-dose. Plasma, red blood cell and sections of the brain were assayed for cholinesterase (ChE) activity at the time of when peak toxic signs were manifested, 2.5 hours post-dose. No animals died as a result of the treatment. Clinical signs of repetitive mouth movements, tremors in the
forelimbs/hindlimbs or whole body, salivation and altered gait were noted in the 125 and 500 mg/kg groups. One male in the 25 mg/kg group exhibited repetitive mouth movements. Twitching of both ears was noted for animals in the 25, 125 and 500 mg/kg treatment groups. Hypothermia was exhibited by the animals in the 500 mg/kg. In Phase I, cholinesterase activity was reduced in a dose-related manner with the activity level ranging from 68.9 to 80.5% and 69.6 to 85.9% of the control activity for the males and females, respectively, in the 5 mg/kg treatment group. In Phase II, at 2.5 mg/kg, female ChE activity in the various brain sections ranged from 78.4 (brain stem) to 86.6% (hippocampus) of the control activity. At 0.5 mg/kg, the activity levels in the brain ranged from 92.1 to 102.8% of control activity. Possible adverse effects: signs of neurotoxicity. NOEL (ChE inhibition): (M) < 5 mg/kg (based upon the brain ChE inhibition exhibited by the males in the 5 mg/kg group), (F) 0.5 mg/kg (based upon the inhibition of ChE in the brain of the females in the 2.5 mg/kg group); NOEL (clinical signs): (M/F) 5 mg/kg (based upon the signs observed in the 25 mg/kg animals). Study supplemental. (Moore, 10/19/01)

108-315 183892 “A Single Oral Dose Study with Acephate Technical in Humans” (S. Freestone and P. McFarlane; Inveresk Research, Elphinstone Research Centre, Tranent, EH33 2NE, Scotland; Project ID. ICR 013072; 5/3/00, 1st Amend. 6/26/00, 2nd Amend. 3/23/01) Four groups of 10 male subjects each and one group of 10 female subjects were included in the study. For each group, 7 people were dosed with the test material and 3 received the lactose placebo. The male groups were treated with one dose in a gelatin capsule of 0.35, 0.7, 1.0 or 1.25 mg/kg of Acephate Technical (lot no. 80121 (SCC), purity: 99.0%). The female group received 1.0 mg/kg of the test material. Each subject was screened prior to treatment in which hematology, clinical chemistry, vital signs and ECG were evaluated. Plasma and red blood cell (RBC) cholinesterase (ChE) activities were measured 6 times prior to dosing with the mean values being used as the base line. During the study, blood samples were recovered at 1, 2, 4, 8, 12, 24, 48 and 72 hours and 7 and 14 days post-dose. ChE activity measurements and analysis of acephate and methamidophos levels were performed. Hematology, clinical chemistry and urinalysis parameters were evaluated at 24 hours post-dose. Vital signs and ECG were measured at 2, 4, 8, and 24 hours post-dose. No treatment-related effects were noted for the vital signs, ECG, hematology, clinical chemistry and urinalysis. Analysis of the ChE activity data revealed a statistically significant % change from baseline for plasma ChE at 12 (-12.77%, p<0.01), 24 (-8.89%, p<0.01) and 48 (-9.12, p<0.001) hours post-dose for the males in the 1.25 mg/kg group and at 8 (12.73%, p<0.05), 12 (-12.08%, p<0.05) and 24 (-10.50%, p<0.01) hours for the females in the 1.0 mg/kg group. For RBC ChE, a statistically significant % change from baseline was noted for the males at 12 hours post-dose (-6.75%, p<0.01). In the pharmacokinetic analysis, the T1/2 elimination ranged from 4.39 to 5.42 hours. The time to maximal concentration in the blood (Tmax) ranged from 1.29 to 2.71 hours. The highest mean concentration of both acephate and methamidophos recovered in the urine occurred during the 0 to 12 hours post-dose interval. For the males, the mean percentage of the administered dose recovered in the urine up to 48 hours post-dose ranged from 43.3% for the 0.35 mg/kg group to 52.5% for the 1.0 mg/kg group. The mean percentage of the administered dose recovered in the urine from 0 to 48 hours post-dose from the 1.0 mg/kg females was 26.0%. No adverse effects indicated. NOEL: (M) 1.0 mg/kg (based upon a statistically significant reduction in the plasma ChE activity for the 1.25 mg/kg males); (F) < 1.0 mg/kg (based upon a statistically significant reduction in plasma ChE activity for the 1.0 mg/kg females). Study supplemental. (Moore, 12/4/01)

108-200 067747 “The Cholinesterase Inhibition Potential of Acephate Technical (SX-1102) Following 4-, 9-, or 13-Week Dietary Administration in Male and Female Rats”; (G.P. Brorby,
and D. W. Rosenberg; Chevron Environmental Health Center, Inc., Richmond, CA; Study No. S-3068; 12/30/87); Thirty Sprague-Dawley rats/sex/group were treated in the diet with 0, 2, 5, 10 or 150 ppm of Orthene Technical (lot no. SX-110, purity: 98.2%) for up to 13 weeks (M, 0, 0.12, 0.28, 0.58, or 8.90 mg/kg/day, F 0, 0.15, 0.36, 0.76 or 11.48 mg/kg/day). Ten animals/sex/group were euthanized after 4, 9 and 13 weeks on study. There were no mortalities during the study. There were no treatment-related clinical signs or effects on food consumption. There was no apparent treatment-related effect on body weight gain. Significant brain cholinesterase (ChE) inhibition was noted for the 5 ppm group and above for both sexes after 4, 9 and 13 weeks of treatment (p<0.01) (% of control activity: 5 (M) 92.5 to 92.7%, (F) 89.3 to 91.2%, 10 (M) 85.8 to 89.1%, (F) 83.1 to 88.5%, 150 (M) 48.3 to 52.7%, (F) 45.2 to 54.0%). For the 2 ppm treatment group, only the females demonstrated significant brain ChE inhibition at all of the time points (p<0.01) (% of control activity: 90.3 to 91.9%). A dose-response for ChE inhibition in the plasma and red blood cells was not well demonstrated with statistical significance only at the 150 ppm treatment level. The necropsy examination did not reveal any treatment-related lesions. Possible adverse effect: inhibition of brain cholinesterase; NOEL: (M) 2 ppm (0.12 mg/kg/day) (based upon significant brain ChE inhibition in the 5 ppm treatment group, (F) < 2 ppm (< 0.15 mg/kg/day) (based on the significant brain ChE inhibition in the 2 ppm treatment group). Study acceptable. (Moore, 2/27/02)

108-0354  238758  Brorby, G. P. and D. W. Rosenberg, “The cholinesterase inhibition potential of Acephate Technical (SX1102) following dermal administration in male and female rats,” Chevron Environmental Health Center, Inc., Richmond, CA, 11/24/86. Laboratory Study # SOCAL 2210. Dosing material was Acephate Technical, Lot SX-1102, purity 98.2%, prepared in distilled, deionized water containing 0.1% Tween 80. A single treatment was applied to shaved dorsal skin, and left in place for 72 hours. Cholinesterase (plasma ChE, brain and RBC AChE) enzyme inhibition was assessed immediately after 72-hr termination (the key study parameter). Treated males received 0, 7.9, 37, 107, or 201 mg/kg acephate. Treated females received 0, 9.4, 52, 154, or 306 mg/kg acephate. N = 5/sex/dose. NOEL’s for brain AChE inhibition were 37 mg/kg (M) and 52 mg/kg (F). Inhibition at 107 and 201 mg/kg in males was 29% and 31%, respectively. Inhibition at 154 and 306 mg/kg in females was 38% and 51%, respectively. NOEL’s for plasma ChE were 7.9 mg/kg (M) and 52 mg/kg (F). NOEL’s for RBC AChE were 7.9 and 9.4 mg/kg for M and F, respectively. Investigators’ proposed NOEL’s for ChE inhibition were generally higher than those proposed in this review. There were no evident clinical signs at any dose level. Valid supplementary study. Aldous, 5/5/08.

DEVELOPMENTAL NEUROTOXICITY

328  206825  “Dietary dose range-finding developmental neurotoxicity study of acephate technical in rats.” (Argus Research, October 30, 2001 draft protocol) This document is the draft protocol 222-002P for a developmental neurotoxicity study in rats. The protocol indicates that 15 females per group will be given diets containing 0, 5, 25, 50 and 100 ppm from day 6 of presumed gestation to day 22 of lactation. The dose selection was based on a subchronic neurotoxicity study in adults (record 153408 in volume 286) in which it was stated that no inhibition of cholinesterase was seen through week 7 at 5 ppm. Samples for RBC, plasma and brain cholinesterase activity will be collected on day 20 of presumed gestation (5 dams) or day 22 of lactation (10 dams) from the F0 generation. For F1 offspring, blood and brain samples will be collected from 4 fetuses per sex (DG 20) or two pups per sex per litter (maximum of 10 litters
per group, days 5 and day 22) for cholinesterase determination. A gross necropsy will be performed on dams and pups. This is a draft protocol. No worksheet. (Gee, 10/1/03).

328  206826 “Dietary developmental neurotoxicity study of acephate technical in rats.” (Argus Research, October 30, 2001 draft protocol) This document is a draft protocol (number not assigned) for a study to be conducted following completion of the range-finding study described in record 206825 above. No doses had been selected for the definitive study. Because cholinesterase activity will have been measured in the range-finding study, it will not be determined in the definitive study. Twenty-five presumed pregnant rats will be assigned per group. On day 5 of lactation, pups will be assigned (1/sex/litter) to one of 4 subgroups for day 22 brain weights and histology, water maze and passive avoidance, motor activity and startle habituation and brain weights and pathology at day 70. The draft protocol states that litters with fewer than 8 pups will not be retained. Sexual maturation will be evaluated. Addendum 4 contains the protocol (222-002) for brain weight measurements and histological evaluations. No worksheet. (Gee, 10/1/03)

**  108 - 0331  208523 “Oral (gavage) developmental neurotoxicity study of acephate technical in rats,” (Hoberman, A. M., Argus Research, Laboratory Project VP-23747, Argus protocol 222-002, December 4, 2003). Presumed pregnant Crl:CD7(SD)IGS BR VAF/Plus7 female rats were given doses of 0 (water), 0.5, 1 or 10 mg/kg/day, gestation days 6 through termination of pregnancy and days 0 through 6 of lactation. Pups were dosed at these same doses beginning day 7 of lactation through weaning at day 21. There were 25 dams per dose with 20 litters selected for continuation of the study. There were 5 subsets of pups with 1/sex/litter when possible per subset. Subset 1 were sacrificed on PND 21 for neurohistological examination or ChE assays. Subset 2 were sacrificed on PND 71 following evaluation of passive avoidance and water maze testing. Subset 3 were sacrificed on PND 71 following testing for motor activity (days 13, 17, 21 and 58) and auditory startle habituation (days 22 and 62). Subset 4 were examined outside of the home cage on days 4, 11, 21, 35, 45 and 60 for abnormal signs and sacrificed on PND 71 for neurohistological examination. Subset 5 were sacrificed on PND 21 and were used to standardize litter size and for ChE assays. Litters were standardized to 10/litter on PND 4 with extra pups being used for ChE assays (plasma, RBC and brain). All parental dams survived with no adverse clinical signs. Body weights, weight gains, food consumption and necropsy findings were comparable among groups. Acephate did not affect sexual maturation, learning, motor activity or weight of pups. Administration from gestation day 6 through lactation day 4 did not affect brain, plasma or RBC cholinesterase activity on PND 4. Direct dosing from lactation day 7 through day 21 did result in a statistically significant and biologically relevant reduction in all three measurements at 10 mg/kg/day, PND 21. At 0.5 and 1 mg/kg, brain ChE was reduced > 20%, being significant in male pups (-28.7%** and -33.7%**) and in sexes combined but not in females (-25.4% and -25.8%). Plasma and RBC cholinesterase activities were lower at 0.5 and 1 mg/kg but not clearly dose-related. No affects on brain weight, neuromorphometric or neurohistopathology were noted. Systemic NOAEL = 10 mg/kg/day with brain ChE NOEL < 0.5 mg/kg/day when given directly to pups. No positive control data for neurotoxicity were included in the report. Unacceptable but possibly upgradeable with submission or citation of positive control data mentioned in the text of the report. (Gee, 1/5/04). Positive and negative historical control data were submitted on a CD as record 209229, upgrading the study. (Gee, 2/9/04).

108 - 0337  209229 “Historical control data.” (Argus Research, 2003) The record consists of a CD with 2174 pages. There are seven sections addressing negative and positive control data for
the FOB, motor activity, neuropathology ®. H. Garman), passive avoidance, sexual maturation, and water maze. Data were collected from approximately 1990 through 2001. These data apparently have been accumulated by Argus Research for all of the neuropathology studies conducted at the laboratory. This worksheet is supplemental to the developmental neurotoxicity study in 108-0331, record 208523. These data upgrade that study to acceptable status. (Gee, 2/9/04).

108 - 0332 208524 “Oral (gavage) acute relative sensitivity study of acephate technical in neonatal and adult rats.” (Hoberman, A. M., Argus Research, Laboratory Project VP-25072, Argus protocol 222-005, December 9, 2003) Crl:CD®(SD)IGS BR VAF/Plus® rats were given a single dose of acephate technical (lot AS 40s, batch VDL-622-37a, 99.2%) at doses of 0 (water), 0.5, 1, 2.5 or 10 mg/kg in 10 ml. Pups were dosed on PND 11 or 21 and adults at approximately 68 days of age. There were 10/sex/dose group. Blood and brains were collected at approximately 3 hours after dosing for ChE determinations. The dose of 0.5 mg/kg did not result in toxicologically meaningful reduction in brain or plasma ChE in any group. At 1.0 mg/kg, statistically significant reduction was found in brain ChE in PND 11 male pups (-22.7%**) and adult females (-30.1%). Adult male brain ChE was reduced by 34.7% (NS). Plasma ChE activities were comparable with controls. At 2.5 mg/kg, brain ChE was significantly reduced in both male (-26.6%**) and female (-14.2%) pups on PND 11 but not on PND 21. In adults given 2.5 mg/kg, brain activity was reduced in adult males (-19.8%) but not in adult females (-8.3%). At 10 mg/kg, brain activities were reduced in all groups (PND 11 males, -40.9%**, PND 11 females, -34.6%**; PND 21 males, -34.6%, PND 21 females, -35.8% not significant; adult males, -53.2%** and adult females, -45.2%). Plasma ChE activity was significantly reduced in all groups at 10 mg/kg. RBC activity was quite variable with no clear dose response. Pups were of equal or less sensitivity than adults. All animals survived to scheduled sacrifice with no adverse clinical observations reported. No gross lesions were seen at necropsy. Supplemental study. No worksheet. (1/2/04).

108 - 0333 208525 “Oral (gavage) dosage-range study of acephate technical in adult rats.” (Hoberman, A. M., Argus research, Laboratory Project VP-25064, Protocol 222-004, November 25, 2003) Crl:CD®(SD)IGS BR VAF/Plus® adult rats were treated with acephate technical (lot AS 40s, batch VDL-622-37a, 99.2%). In Part A, fourteen per sex were given a single dose of 0 (water), 2.5 or 10 mg/kg. Two per sex per dose were sacrificed at 0 (pre-dosage), 1, 2, 3, 4, 8 and 24 hours after dosing. Blood was collected for RBC and plasma ChE and brains were excised, weighed and assayed for ChE activity. Peak reduction in brain ChE occurred between 4 and 8 hours at 2.5 mg/kg and between 3 and 4 hours at 10 mg/kg/day, single dose. Peak plasma reduction in ChE activity occurred between 1 and 8 hours. RBC levels were variable with peak reduction around 8 hours post-dose. In Part B, two per sex were given doses of 0, 2.5 or 10 mg/kg/day for 11 days. Blood was collected approximately 3 hours after the final dose and processed for ChE determinations. The brain was excised, weighed and assayed for ChE. Brain ChE was reduced by 40.7% at 2.5 mg/kg and by 67.5% at 10 mg/kg, sexes combined. Plasma ChE was reduced by 18.6% at 2.5 mg/kg and by 54.5% at 10 mg/kg, sexes combined. RBC ChE was lower by 9.8% at the low dose and by 53.3% at the high dose of 10 mg/kg, day 11 of dosing. A gross necropsy was performed on all animals. All animals survived and body weights were comparable. No adverse clinical signs were noted. Supplemental study. No worksheet. (Gee, 1/2/04).

108 - 0334 208526 “Oral (gavage) maternal and fetal exposure study of acephate technical in rats.” (Hoberman, A. M., Argus Research, Laboratory Project VP-25267, Argus protocol 222-
Eight presumed pregnant Crl:CD® \textregistered (SD)IGS BR VAF/Plus® rats were given doses of technical acephate (lot AS 40s, batch VDL-622-37a, purity 99.2%) of 0 (water), 0.5, 1, 2.5, or 10 mg/kg/day on day 6 through day 21 of gestation, 10 ml/kg, given approximately the same time each day. Doses were selected based on studies VP-25056 (record 208528) and VP-25064 (record 208525). Rats were observed before dosing and at 60 minutes and 3 hours post-dosage. On day 21, blood was collected approximately 3 hours after dosing for plasma and RBC cholinesterase and brains were excised, weighed and processed for ChE assay. Fetuses were weighed, examined for gross changes and the blood and brain collected for ChE determinations. All dams survived until scheduled sacrifice. There were no treatment-related findings for clinical observations, body weights, food consumption, or fetal gross changes. Brain weights and brain to body weight ratios were comparable. ChE activity of male and female fetuses were similar. RBC ChE activity was variable with no evident dose-dependency up to 10 mg/kg/day. Plasma ChE of dams was lower at 10 mg/kg/day (-55.0 %**) and of combined fetuses (-60.0%**). At 2.5 mg/kg/day, plasma activity was reduced by 21% (not statistically significant) in dams and by 31%** in fetuses, sexes combined. At 0.5 and 1 mg/kg, plasma activity in male fetuses was also reduced (-21.7% at -.5 and 13.3% at 1 mg/kg/day). Brain ChE activity was significantly reduced in dams at all doses (-16.7%*, -18.1%*, -40.8%** and -61.5%** with increasing dose). The decreases at 0.5 and 1 mg/kg were considered by the author to be within the variability of the assay. For fetuses, brain cholinesterase was considered reduced at 10 mg/kg (-40.0%**). Other values (-7.3%, -12.1%* and -14.3%*) were considered by the author to be within the variability of the assay. [*\(p<0.05\), **\(p<0.01\)] The conclusions were that exposure of the dam results in fetal exposure, male and female fetuses respond similarly and fetuses were found to be equally or less sensitive than the dams at 2.5 and 10 mg/kg/day. Supplemental study. No worksheet. (Gee, 12/31/03).

Technical acephate (lot AS 40s, batch VDL-622-37a, 99.2%) was used. The purpose was to compare the effects of acephate on neonatal (part A) and adult (part B) rats, including cholinesterase inhibition. Doses were 0 (water), 0.5, 1, 2.5 or 10 mg/kg/day, given PND’s 11 through 21 (11 days total) to neonates and to adults (males were 77 days and females were 71 days of age) for 11 days at the same doses. Doses were selected based on studies VP-25056 (record 208528) and VP-25064 (record 208525). Part A: Pups: One pup/sex/group/litter (total of 10/sex) were given the above doses. Clinical observations were made each day before dosing and approximately 60 minutes after dosing as well as at 3 hours post-dosage. Pups were sacrificed on PND 21 and a gross necropsy conducted. Blood was collected 3 hours after dosing for RBC and plasma ChE determinations. The brain was excised for ChE levels. All pups survived until sacrifice and no clinical signs or gross lesions were observed. Body weights were generally comparable. Part B: Adults with ten/sex/dose: Observations were made prior to dosing and at 60 minutes and 3 hours post-dosage. A gross necropsy was performed and blood drawn for ChE determinations. Brains were excised, weighed and assayed for ChE. Cholinesterase: At 0.5 mg/kg/day, brain ChE was significantly inhibited by 28.5%** in adult males but not in adult females (-8.2%) or in pups (M: -5.2%; F: +5.2%). At 1 and 2.5 mg/kg, significant inhibition of brain ChE occurred in all groups except female pups (both doses). At 10 mg/kg, similar levels of inhibition of brain ChE occurred in pups and adults (>50 %). For plasma ChE, no inhibition occurred at 0.5 mg/kg/day in any group. At 1 mg/kg, significant inhibition was found in adult females (-34.9%**) but no other group. At 2.5 mg/kg, inhibition was greater in adults (-33.9 %*, sexes combined) than in pups

108 - 0335 208527 “Oral (gavage) repeated dose relative sensitivity study of acephate technical in neonatal and adult rats.” (Hoberman, A. M., Argus Research, Laboratory Project VP-25081, Argus protocol 222-006, conducted in Sept./Oct., 2002, report date of November 25, 2003) Crl:CD®(SD)IGS BR VAF/Plus® rats were used. The purpose was to compare the effects of acephate on neonatal (part A) and adult (part B) rats, including cholinesterase inhibition. Doses were 0 (water), 0.5, 1, 2.5 or 10 mg/kg/day, given PND’s 11 through 21 (11 days total) to neonates and to adults (males were 77 days and females were 71 days of age) for 11 days at the same doses. Doses were selected based on studies VP-25056 (record 208528) and VP-25064 (record 208525). Technical acephate (lot AS 40s, batch VDL-622-37a, 99.2%) was used. Part A: Pups: One pup/sex/group/litter (total of 10/sex) were given the above doses. Clinical observations were made each day before dosing and approximately 60 minutes after dosing as well as at 3 hours post-dosage. Pups were sacrificed on PND 21 and a gross necropsy conducted. Blood was collected 3 hours after dosing for RBC and plasma ChE determinations. The brain was excised for ChE levels. All pups survived until sacrifice and no clinical signs or gross lesions were observed. Body weights were generally comparable. Part B: Adults with ten/sex/dose: Observations were made prior to dosing and at 60 minutes and 3 hours post-dosage. A gross necropsy was performed and blood drawn for ChE determinations. Brains were excised, weighed and assayed for ChE. Cholinesterase: At 0.5 mg/kg/day, brain ChE was significantly inhibited by 28.5%** in adult males but not in adult females (-8.2%) or in pups (M: -5.2%; F: +5.2%). At 1 and 2.5 mg/kg, significant inhibition of brain ChE occurred in all groups except female pups (both doses). At 10 mg/kg, similar levels of inhibition of brain ChE occurred in pups and adults (>50 %). For plasma ChE, no inhibition occurred at 0.5 mg/kg/day in any group. At 1 mg/kg, significant inhibition was found in adult females (-34.9%**) but no other group. At 2.5 mg/kg, inhibition was greater in adults (-33.9 %*, sexes combined) than in pups (-
21.1%**). At 10 mg/kg, plasma ChE was inhibited to a greater extent in adults, sexes combined (-53.7%**), than in pups (-38.9%**). The RBC data did not indicate any clear pattern. The conclusion of the author was that adult rats were as sensitive or more sensitive than pups to cholinesterase inhibition by acephate. Supplemental study. No worksheet. (Gee, 12/31/03).

108 - 0336 208528 “Oral (gavage) dosage-range study of acephate technical in neonatal rats.” (Hoberman, A. M., Argus Research, Laboratory Project VP-25056, Argus protocol No. 222-003, conducted in May/June of 2002, December 9, 2003) The study was conducted in three parts, using acephate technical, lot number AS 40s, batch VDL-622-37a, 99.2% with water as the vehicle. Neonatal Crl:CD®(SD)IGS BR VAF/Plus® rats were used. Part A: One pup/sex/litter (4 litters, n = 4/sex) were given a dose of 0 (water), 0.5, 2.5, 5 or 10 mg/kg on postnatal day 11 or 21. Pups were observed at 60 minutes, 2, 3 and 4 hours and at the 24-hour post-dose sacrifice. Body weights were recorded. A gross necropsy was conducted. F0 females were discarded without further evaluation. All pups survived until scheduled sacrifice with no adverse clinical signs observed. Body weights and weight gains were comparable among groups. Part B: Four/sex/dose were given doses of 0 (water), 0.5, 2.5, 5 or 10 mg/kg technical acephate on postnatal days 11 through 21 by gavage. Clinical observations were recorded daily before dosing and 60 minutes after dosing. Body weights were recorded. Pups were sacrificed on PND 22, a gross necropsy conducted and any lesions retained. All pups survived until scheduled sacrifice with no adverse clinical signs observed. Body weights and weight gains were comparable among groups. Part C: Two pups/sex/litter (7 litters) were given doses of 0, 5 or 10 mg/kg on PND 11 or 21. Pups were observed daily for clinical signs with body weights recorded on day of dosing and at scheduled sacrifice. Blood samples were collected for cholinesterase determinations at 0 (pre-dose), 1, 2, 3, 4, 8 and 24 hours post-dosage. Samples were processed for RBC and for plasma ChE levels. Brains were collected for ChE. Duplicate analyses were performed per sample. Two pups per sex were used per time point. All pups survived until scheduled sacrifice and all appeared normal at necropsy. Due to the small number (2) per sampling time per sex, the peak time of inhibition of ChE was difficult to determine but the author concluded that the maximal inhibition occurred between 2 and 8 hours with no significant difference with sex or with age (PND 11 versus PND 21). A peak sampling time of 3 hours was proposed. Inhibition of brain, plasma and RBC ChE was slightly greater at 10 mg/kg. Supplemental study. No worksheet. (Gee, 12/30/03)

MISCELLANEOUS

Guidance for the Reregistration of Pesticide Products Containing Acephate as the Active Ingredient, EPA, September, 1987, gives the following data gaps for acephate: Twenty-one day inhalation study in rats, chronic toxicity in the rat to determine the NOEL for brain cholinesterase inhibition and rat reproduction study to establish the NOEL - this has been satisfied with DPR Record #060979, not included in the EPA review. Acephate has been classified as a class C carcinogen or “possible” human carcinogen based on the increase in liver adenomas/carcinomas and hyperplastic nodules in female mice only at the high dose at term plus the positive findings in in vitro mutagenicity tests. In vivo studies were negative for genotoxicity. Methamidophos: Technical acephate contains 0.9 to 1.2 % w/w methamidophos*, a cholinesterase inhibitor and a metabolite of acephate as well as a contaminant. By acute studies, it is highly toxic, being category I. Methamidophos was not oncogenic at 25 ppm in rats and not teratogenic in rabbits (2.5 mg/kg) or in rats (3.0 mg/kg). In a 1-year dog study and a 2-year rat
study, inhibition of brain cholinesterase was observed at 2 ppm (0.05 mg/kg/day) (LDT). The EPA reregistration document identifies a rat reproduction study and mutagenicity studies as remaining data gaps.

Methylthioacetate: This is an impurity* in the currently registered product. According to EPA, additional studies (acutes and 90-day dermal in rabbits) are required. Also, they indicate that a battery of mutagenicity tests in addition to the positive mouse lymphoma test are needed.

*Chevron's rebuttal letter of 5/5/88 states that current manufacturing processes produce > 99.9% pure acephate.

Twelve studies on methylthioacetate to support continued registration of acephate were submitted by Valent U.S.A. Corp. with a letter dated 12/5/88. The studies include acute, subchronic and mutagenicity. These studies are under tolerance number 51656. One-liners created in the 950 review follow.


SUBCHRONIC, DERMAL

51656-003 72296 “Ninety Day Dermal Toxicity Study in Rabbits with Methylthioacetate (MTA)” (Chevron Environmental Health Center, Inc. No. CEHC 2822, 1-15-88)
Methylthioacetate, SX-1732, 98.9%, was placed on the backs of New Zealand White rabbits for 6 hours/day, 5 days/week at dose levels of 0, 5, 20 or 60 mg/kg, deaths by percent were 7, 50, 53 and 50, respectively. There were 15/sex/group initially except for the low dose group which had 10/sex. The majority of deaths were attributed to mucoid enteritis. Clinical signs include inappetence, diarrhea, no stool and decreased activity related to mucoid enteritis. At 20 and 60 mg/kg severe skin irritation occurred until the site of application was varied on the animal. Histopathology revealed no compound related lesions of the optic nerve or liver, the known target organs in acute studies. Supplemental since not an active pesticidal ingredient, otherwise UNACCEPTABLE, and not upgradeable. The occurrence of disease compromised the value of the study and reduced animal numbers to unacceptable levels. D. Shimer, 7/13/89.

108-0353 237783 Hoffman, G. M., “Acephate Technical: A 21-day dermal toxicity study in rats,” Huntingdon Life Sciences, East Millstone, NJ, 5/26/00. Laboratory Study # 99-2637. Ten Crl: CD® (SD) IGS BR VAF/Plus® rats/sex/group were dosed by dermal application to clipped dorsal skin with Acephate Technical (Lot No. VJI-001TG-21, purity 98.8%), at 0, 20, 30, 40, or 50 mg/kg/day. Dosing was 5 days/week over 3 weeks, for a total of 16 applications: necropsy was on the day following the 16th treatment. Applications were made in physiological saline (0.9%), 1 ml/kg b.w. Treated skin was covered with gauze and then secured with Elastoplast®. At the end of each 6-hr exposure period, dressings were removed, and surface was wiped with dry gauze. Investigators evaluated for possible skin lesions at the application site, clinical signs, cholinesterase changes (plasma ChE, RBC AChE, and brain AChE), body weight, food consumption, and gross pathology. None of these parameters indicated treatment effects. NOEL for protocol parameters = 50 mg/kg/day (highest dose tested). Valid supplementary study, addressing several key parameters, however study design did not include all
parameters relevant to a guideline subchronic dermal toxicity study. Aldous, March 13, 2008.

NOTE: Page 22 of this report cites a previous 21-day dermal study (HLS Study No. 97-2547), which yielded a NOEL of 12 mg/kg/day. That study is not found on the DPR index of Acephate reports. No other rat subchronic dermal toxicity studies have been indexed at DPR as of March 12, 2008.

**108-0354 238757** Blaszcak, D., “Acephate Technical: A 21-day dermal toxicity study in the rat,” Huntingdon Life Sciences, East Millstone, NJ, Feb. 5, 1998. Laboratory Study # 97-2547. Ten Crl: CD® (SD) BR VAF/Plus® rats/sex/group were dosed by dermal application to clipped dorsal skin with Acephate Technical (Lot No. R23044/VS-9B-40, purity 97.8%), at 0, 12, 60, or 300 mg/kg/day. Dosing was 5 days/week over 3 weeks, for a total of 15 or 16 applications: necropsy was on the day following the last treatment. Applications were made in physiological saline (0.9%), 1 ml/kg b.w. Treated skin was covered with gauze and then secured with Elastoplast®. At the end of each 6-hr exposure period, dressings were removed and surface was wiped with dry gauze. Investigators evaluated for possible skin lesions at the application site, clinical signs, cholinesterase changes (plasma ChE, RBC AChE, and brain AChE), body weight, food consumption, and gross and microscopic pathology (the latter in controls and high dose rats only). NOEL = 12 mg/kg/day (F) and 60 mg/kg/day (M), based exclusively on brain acetylcholinesterase (AChE) inhibition. This study is considered alongside DPR Record No. 237783 by Hoffman (DPR Document No. 108-0353: Huntingdon Laboratory Study # 99-2637) to assess brain AChE NOEL. Record No. 237783 showed no hint of ChE inhibition in plasma, RBC’s, or brain in the range tested (up to 50 mg/kg/day). Since the NOEL in the present study is based strictly on brain AChE inhibition, the composite NOEL for the combined studies is 50 mg/kg/day, based on AChE inhibition in females at 60 mg/kg/day in the present (primary) study. Brain AChE inhibition at 300 mg/kg/day in this study was 9% and 14% compared to controls, without evident cholinergic signs. This suggests that acephate has limited capacity to elicit clinically important AChE inhibition. Aldous, 4/17/08.

METHYLTHIOACETATE MUTAGENICITY STUDIES

GENE MUTATION (METHYLTHIOACETATE )

51656-004 072297 “Salmonella/Mammalian Microsome Plate Incorporation Mutagenicity Assay (Ames Test) with Methylthioacetate (SX-1732),” (Microbiological Associates, Study No. T5771.50104, 12-23-87) Methylthioacetate (98.2% pure; LOT #: SX-1732), was tested for mutagenicity with Salmonella typhimurium strains TA98, TA100, TA1535, TA1537 and TA1538 at concentrations of 10,000, 5000, 2500, 500 or 100 µg/plate (triplicate plates). Assays were done in the presence and absence of metabolic activation. A confirming repeat test was performed. No increase in the number of revertants was observed. No adverse effects. Supplemental. This is not a registered pesticide, but a contaminant present at a very low concentration in Acephate. D. Shimer & M. Silva, 3/30/90.

CHROMOSOME EFFECTS (METHYLTHIOACETATE )
51656-004 072298 “Clastogenic Evaluation of Methylthioacetate (SX-1732) in the Rat Bone Marrow Cytogenetic Assay Following a Four-Day Inhalation Pilot Study,” (Hazleton Laboratories America, Inc., Study No. 2107-147, 11-12-87). Fischer 344 rats, 5/sex/group, were exposed to methylthioacetate (Lot #: SX-1732; 98.2% pure) vapors at concentrations of 400, 600 or 800 ppm for 6 hours/day for 4 consecutive days. Animals were sacrificed 19 hours after their last exposure and 50 cells/dose/animal were scored (50 spreads/animal). NOEL < 400 ppm (Clinical signs were observed at ≥ 400 ppm; body weights in both sexes were significantly decreased at ≥ 400 ppm; there was a significant decrease in food consumption at ≥ 400 ppm; 80% mortality--all males and 3/5 females--at 800 ppm). NOAEL = 600 ppm. No positive control, was used in this study, however, the high dose was acceptable, due to the degree of mortality at 800 ppm. No adverse effects. Supplemental. The study was considered to be a pilot study. This is not a registered active ingredient, but a contaminant in Acephate. D. Shimer & M. Silva, 3/29/90.

DNA DAMAGE/REPAIR (METHYLTHIOACETATE)

51656-004 072299 “Micronucleus Assay in Mouse Bone Marrow Erythrocytes Following Inhalation Exposure to Methylthioacetate (SX-1763, 99.2% Purity),” (Chevron Environmental Health Center, Inc., No. CEHC 2751, 1-15-88). Methylthioacetate (Lot #: SX-1763; 99.2% pure) was used, as a vapor, on Swiss albino mice (≥ 15 mice/sex/group) for 4 hours at actual concentrations of 0, 445, 651 or 796 ppm. Five/sex/group were sacrificed at 24, 48 and 72 hours after the start of exposure. 1000 PCE were examined/slide/animal, 1000 cells were counted to determine NCE:PCE ratio. No adverse chromosome effects. No treatment related increase in the number of micronucleus was observed, however, 5 animals died at 796 ppm and histopathology revealed treatment related lesions in lungs of all methylthioacetate dosed animals. Supplemental. This is not a registered ingredient, but has been submitted because it is a contaminant in Acephate. D. Shimer & M. Silva,

OTHER

315 - 0281 211501 “A study of the effects of Orthene and Monitor on plasma and erythrocyte cholinesterase activity in human subjects during subacute oral administration.” (Garofalo, M., Industrial Bio-Test Laboratories, Inc., IBT No. 636-02498, Report No. 98473, March 7, 1973) Note: This study has been evaluated by US EPA as “S” for supplementary and not as “I”, invalid. Pages 49 and following contain evaluations of the study made in 1977/1978, comparing the report with the available raw data. The major problem was the lack of some raw data to support the values in the IBT report, especially for the 0.4 mg/kg/day females. Study: The test materials were mixtures of methamidophos (Monitor) and acephate (Orthene) in ratios of either 1:9 or 1:4 parts of Monitor/Orthene. The materials were taken three times daily in corn oil in gelatin capsules for daily doses of 0.1, 0.2, 0.3 or 0.4 (females only) mg/kg/day. The subjects were seven male and seven female volunteers with 2/sex in the control and 1:4 groups and 3/sex in the 1:9 group. Ages ranged from 21 to 48 years. Exposure was for a total of 21 consecutive days for 0.1, 0.2 and 0.3 mg/kg/day and 10 (?) days for 0.4 mg/kg/day in females. Baseline plasma and erythrocyte cholinesterase activities were determined 5 times during the 2 weeks preceding exposure. ChE activities were determined on days 1, 3, 7, 14 and 21 during the test period. Each subject was given increasing doses of the test materials, same ratio, in sequence of increasing dose. After exposure to 0.3 mg/kg/day, there was a 7-day rest period
with evaluation of ChE activities. ChE was determined by an AutoAnalyzer using the procedure of Levine, J. B. et. al. Limited hematology parameters were also evaluated pretest and at the end of the exposure period. Additional observations included blood pressure, muscle tone, pulse rate, pupil size, light reflex, eye accommodation, knee jerk, tongue tremor and finger tremor. Subjects were also to report any abnormal symptoms. Results There was no effect on erythrocyte ChE in any group. There was no effect on ChE at 0.1 mg/kg/day with either ratio. At 1:4, 0.2 mg/kg, plasma ChE was depressed in both sexes (considered to be the minimum effect level by the author) but not at 1:9 ratio. At 1:9, 0.3 mg/kg/day caused depression in plasma ChE in males [1:4 was not tested at this dose]. At 0.4 mg/kg/day, 1:9, in three females, plasma, but not erythrocyte, ChE was depressed. ChE was considered affected if there were two consecutive measurements with depression greater than 2 standard deviations below the mean pretest value. The report states that there were no significant effects on hematology or the other parameters evaluated. Individual data were presented for hematology and clinical chemistry. Corrected pages, based on raw data, are included in the reevaluation pages. Supplemental study. No worksheet. (Gee, 6/18/04)